{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 65 of 169', '10 Trial schedule and assessments', '10.1 Overview', 'Evaluations to be done at each visit are shown in the schedule of procedures (SoP) in', 'Section 4. Links to the relevant SoPs are given in Panel 9. Refer to Section 7.1 for further', 'details on the trial design.', 'Panel 9 Overview of schedules of procedures', 'Period', 'Start', 'Stop', 'Follow-up', 'SoP', 'visit', 'Screening and initial treatment', 'Week -6\u00b9', 'Week 16', 'Not applicable', 'Panel 2', 'Maintenance treatment\u00b2', 'Week 16', 'Week 52', 'Week 66', 'Panel 3', 'Open-label treatment\u00b3', 'Week 16', 'Week 52', 'Week 66', 'Panel 4', 'Selected countries only:', 'Week 52', 'Week 68', 'Week 82', 'Panel 5', 'short-term extension4', '1. For subjects who do not require a wash-out, screening will start at Week -2 (Section 7.1).', '2. Subjects achieving a clinical response at Week 16 will continue into maintenance treatment that will', 'continue until Week 52 (Section 7.1).', '3.', 'Any subject that does not achieve a clinical response at Week 16 will be treated with open-label', 'tralokinumab 300 mg Q2W with optional use of TCS. In addition, subjects who meet certain criteria during', 'maintenance treatment will also be transferred to open-label treatment (Section 7.1).', '4.', 'Subjects who transfer to open-label tralokinumab treatment at Week 16 will continue an additional 16 weeks', 'of open-label treatment in order to secure at least 52 weeks active therapy (Section 7.1).', 'Q2W, every 2 weeks; SoP, schedule of procedures; TCS, topical corticosteroids.', 'During the course of the trial, subjects may need to be seen at unscheduled visits. The', \"assessments to be performed at an unscheduled visit are left to the investigator's discretion\", '(could include any assessment performed at an early termination visit).', 'Assessments/procedures at any trial visit should be performed in the following order:', 'PROs.', 'Investigator assessments (performed only by adequately trained investigators;', 'the same investigator should perform all the evaluations for a given subject', 'throughout the entire trial period) in the following order:', '1. SCORAD component C, then component A and B.', '2. IGA.', '3. EASI.', 'Safety and laboratory assessments.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 66 of 169', 'Other assessments (skin microbiology, serum biomarkers, skin biopsies,', 'photographs).', 'Administration of IMP.', 'Subjects participating in the trial will be under careful supervision of a dermatologist or', 'allergist. Investigators must be experienced in treating AD and have documented experience', 'and/or training in use of the assessments required by the protocol and must be either a', \"physician, certified physician's assistant, or advanced registered nurse practitioner. The\", 'investigators performing the assessments must not be involved in the administration of', 'IMP (Section 9.3.1).', '10.2 Assessments performed only at screening/baseline', 'Assessments performed only at the screening and/or baseline visit include: assessment of', 'eligibility criteria (including review of scores on the Columbia-Suicide Severity Rating Scale', '[C-SSRS] Screening version), demographics, medical history, height and weight, and body', 'surface area (BSA) affected by AD. These are described in further detail below. Laboratory', 'tests include hepatitis B, hepatitis C, HIV-1, HIV-2, and serum pregnancy test (Sections 10.4.4', 'and 10.4.5).', '10.2.1 Columbia-Suicide Severity Rating Scale', 'The C-SSRS Screening version is a rater-administered instrument used to assess severity of', 'suicidal ideation and suicidal behaviour through a series of simple, plain-language questions', '(36). The C-SSRS must be completed at screening to check that exclusion criterion no. 24', 'does not apply.', '10.2.2 Demographics', 'The following demographic data will be recorded:', 'Month and year of birth', 'Sex', 'Race: American Indian or Alaska Native, Asian (Japanese), Asian (others),', 'Black or African American, Native Hawaiian or Other Pacific Islander, White,', 'Other', 'Ethnic origin (self-reported by the subject): Hispanic or Latino, not Hispanic or', 'Latino', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}